Effects of droxicam on in vivo prostaglandin synthesis and ex vivo platelet aggregation

Methods Find Exp Clin Pharmacol. 1987 Apr;9(4):209-13.

Abstract

Droxicam, similar to piroxicam, inhibits in vivo renal synthesis of PGF2 alpha. This study was performed in rats; droxicam and piroxicam were administered orally at doses of 0.5, 1.2 and 8 mg/kg. Inhibitory activity of the two compounds was similar (40-60%) but showed no dose-effect relationship. Maximum inhibition was obtained with the 1 mg/kg dosage. In dogs droxicam has shown a clear inhibitory effect on arachidonic acid induced ex vivo platelet aggregation. Droxicam was administered orally at a dose of 2 mg/kg. Maximum inhibition (-40%) was achieved 24 hr post-administration and the effect was sustained up to 72 hr (-23%).

MeSH terms

  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
  • Arachidonic Acid
  • Arachidonic Acids / urine
  • Dinoprost
  • Dogs
  • Kidney / metabolism
  • Male
  • Piroxicam / pharmacology
  • Platelet Aggregation / drug effects*
  • Prostaglandin Antagonists
  • Prostaglandins F / biosynthesis*
  • Prostaglandins F / urine
  • Pyridines / pharmacology*
  • Rats
  • Rats, Inbred Strains

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Arachidonic Acids
  • Prostaglandin Antagonists
  • Prostaglandins F
  • Pyridines
  • Piroxicam
  • Arachidonic Acid
  • Dinoprost
  • droxicam